🇺🇸 FDA
Patent

US 7592322

RNAi modulation of RSV, PIV and other respiratory viruses and uses thereof

granted A61KA61K2121/00A61P

Quick answer

US patent 7592322 (RNAi modulation of RSV, PIV and other respiratory viruses and uses thereof) held by Alnylam Pharmaceuticals, Inc. expires Mon Sep 17 2029 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Alnylam Pharmaceuticals, Inc.
Grant date
Tue Sep 22 2009 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 17 2029 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
6
CPC classes
A61K, A61K2121/00, A61P, A61P11/00, A61P31/14